Optibrium and ChemAxon Collaborate
News Apr 15, 2015
Optibrium™ and ChemAxon™ have announced the results of a collaboration to integrate ChemAxon’s Plexus™ with Optibrium’s StarDrop™ software suite. The integration of these platforms further enables researchers to develop strategies for efficient, high quality compound library design.
The StarDrop software platform from Optibrium facilitates multi-parameter optimisation, property prediction and data visualisation to guide the design of high quality compounds for drug discovery projects. ChemAxon’s Plexus is a web based collaborative discovery platform which enables scaffold- and reaction-based enumeration of compound libraries.
As a result of the collaboration, a seamlessly integrated workflow and user interface is available in StarDrop for the application of Plexus to enumerate compound libraries. These are returned as data sets within StarDrop for detailed analysis, visualisation and selection of compounds with an optimised balance of the properties required for success.
Matthew Segall, CEO of Optibrium, will provide an overview of the results of this collaboration at ChemAxon's European User Group Meeting being held in Budapest, Hungary, May 19-20.
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
Computer Program Helps Find Ways to Repurpose Existing DrugsNews
Researchers have developed a computer program to find new indications for old drugs. The computer program, called DrugPredict, matches existing data about FDA-approved drugs to diseases, and predicts potential drug efficacy.READ MORE
Big Data From Social Media Helps Combat Prescription Drug CrisisNews
Researchers have conducted a critical review of existing literature to determine whether social media big data can be used to understand communication and behavioral patterns related to prescription drug abuse.READ MORE